Archive for January, 2021
Wall Street is Poised for Disruption, Part One January 30, 2021
It is Time for Wall Street Wall Street Business Practices to Be Disrupted The frenzy of news flow around the short squeeze on GameStop might be viewed as some kind of one off, weird trading situation precipitated by retail speculators. Old Wall Street hands are saying that it will pass, although they also suggest that […]
Northwest Biotherapeutics and the Robinhood Trading Phenomenon (NWBO), Buy, $1.59)
Stunning Stock Price Movements for GameStop and AMC Entertainment There has been a lot of news coverage this week about the trading of two stocks which have for some time been the subjects of intense short selling: the videogame retailer GameStop Corp.(GME)and the theater chain AMC Entertainment (AMC). On January 21, GME closed at $43.03 […]
Cryoport (CYRX, Buy, $72.30) Kymriah Sales are Strong and Equity Offering Was Well Received
Kymriah Sales Were Strong in 4Q, 2020 Novartis just reported 4Q, 2020 worldwide sales for Kymriah of $141 million. This was an increase of 47% from 4Q, 2019 and a sequential increase of 16% from 3Q, 2020. Novartis commented that sales grew strongly in Europe, US and Japan and that coverage continued to expand, with […]
Cryoport: Comments on Just Completed Equity Offering and Surprising 15% Surge in Stock Price (CYRX, Buy, $73.75)
Overview I wanted to give subscribers a quick overview of the just completed equity offering and the surprising 15% surge in the stock price after the deal was announced. This note is a quick synopsis. I am working on other reports that will include a model for sales and earnings, potential price targets and other […]
Cytokinetics: Approval of Merck’s Heart Failure Drug Vericiguat Increases My Confidence for Approval of Omecamtiv
The FDA approval of Merck’s new heart failure drug, vericiguat, has meaningful implications for whether it will approve omecamtiv. Vericiguat’s approval meaningfully increases my already strong confidence that the FDA will also approve omecamtiv. The vericiguat trial enrolled 5,050 patients with ejection fractions less than 45. The data underlying its approval is quite similar to […]
Cytokinetics: A Deep Dive into the Potential for Omecamtiv (CYTK, Buy, $19.86)
Investment Overview Cytokinetics has three highly valuable pipeline assets whose aggregate value in my view substantially exceeds its current market valuation of $1.4 billion: Omecamtiv mecarbil just completed the GALACTIC-HF phase 3 trial in heart failure. The trial met its primary endpoint with a p value of 0.025 and there were no safety issues, but […]
Antares: Encouraging Revenue Guidance (ATRS, Buy, $4.00)
Key Point I think that the stock has the potential to double in 2021. New Revenue Guidance Antares has just issued guidance that 2020 revenues are expected to be in the range of $145 to $150 million which compares to $124 million in 2020. The midpoint of this range represents a 19% increase from 2019. […]